Skip to main content
3 minutes reading time (618 words)

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients with follicular lymphoma (FL).

Oncology Data Advisor: Today, we are here with Dr. Tessoulin. Would you like to begin by introducing yourself and your research interest?

Benoit Tessoulin, MD, PhD: Yes. Thank you, Lyn, for having me. I'm Benoit Tessoulin, I'm a Medical Doctor and the Head of the Lymphoma Department at the Nantes University Hospital in France. As for a special interest, it would be lymphoma, of course.

Oncology Data Advisor: Awesome, glad to have you. To begin with the interview, would you like to give us an overview of the ELM-2 study and what it's set to accomplish?

Dr. Tessoulin: Yes, so what we reported here were the patient-reported outcomes (PROs) of the follicular lymphoma cohort of the ELM-2 study. ELM-2 is the monotherapy trial with odronextamab, which is a bispecific antibody.

Oncology Data Advisor: Awesome, and what results did you present?

Dr. Tessoulin: So, the result demonstrated, first, that the drug is highly active with reasonable response rates of 80%—mostly complete responses. Also, the quality of life of the patients was either well-maintained or even improved over time from baseline through Week 50, which is in favor of benefit from the treatment.

Oncology Data Advisor: Awesome, and what kind of drug is odronextamab and how does it work in the relapsed/refractory FL landscape?

Dr. Tessoulin: Odronextamab is an off-the-shelf bispecific antibody which engages CD20 on the B cells and CD3 on the T cells, thus initiating some T-cell–mediated cytotoxicity towards B cells.

Oncology Data Advisor: Were there any limitations your team experienced while conducting the study?

Dr. Tessoulin: There were some limitations which relate to the design of the trial because it's a phase 2, so most of the findings are some of hypothesis-generating data. So, thus far there have not been that many limitations because completion rates for the PROs were quite high from baseline through Week 50, more than 75%. So, it's quite a very good completion rate for this kind of study.

Oncology Data Advisor: Definitely. That's awesome to hear. Do you have plans for a phase 3 trial at all or further study of this?

Dr. Tessoulin: Yes, so for FL, there are three randomized controlled trials to come, two in the first-line setting and one in the refractory/relapsing setting, versus rituximab/lenalidomide.

Oncology Data Advisor: Incredible. Well, thank you so much for your time today. We really appreciate your research.

Dr. Tessoulin: Thank you for having me.

About Dr. Tessoulin

Benoit Tessoulin, MD, PhD, is the Head of the Lymphoma Department at the Nantes University Hospital in France. Dr. Tessoulin's research interest and passion revolve around mantle cell lymphoma, non-Hodgkin lymphoma, as well as multiple myeloma. He is an active participant in clinical research where he has authored and co-authored a plethora of studies in the past 15 years.

For More Information

Tessoulin B, Cho SG, Taszner M, et al (2023). Maintenance of moderate to high levels of functioning and quality of life with odronextamab monotherapy in patients with relapsed or refractory follicular lymphoma. Presented at: American Society of Hematology Annual Meeting 2023. Abstract 669. Available at: https://ash.confex.com/ash/2023/webprogram/Paper181942.html

Transcript edited for clarity. Any views expressed above are the speaker's own and do not necessarily reflect those of Oncology Data Advisor. 


Related Posts